Cladribine is an oral synthetic purine analog that depletes lymphocytes and induces a dose-dependent reduction of T and B cells. It was approved for the therapy of highly active relapsing-remitting multiple sclerosis. Given cladribine's mechanism of action, an increased risk of malignancies was suspected from the number of cancers that occurred...
-
July 25, 2020 (v1)Journal articleUploaded on: December 4, 2022
-
November 2024 (v1)Journal article
International audience
Uploaded on: January 13, 2025 -
September 2024 (v1)Journal article
Radiologically isolated syndrome (RIS) is the earliest stage in the disease continuum of multiple sclerosis (MS). RIS is discovered incidentally in individuals who are asymptomatic but have typical lesions in the brain and/or spinal cord suggestive of demyelination. The 2009 and revised 2023 RIS criteria were developed for diagnosis....
Uploaded on: September 20, 2024 -
2022 (v1)Publication
In this Roadmap, Marrie and colleagues set out the steps needed to improve our understanding of the multiple sclerosis (MS) prodrome and develop standardized criteria for identifying individuals with prodromal MS, thereby facilitating trials of interventions that could slow progression to classical MS.A prodrome is an early set of signs or...
Uploaded on: February 14, 2024 -
June 2022 (v1)Journal article
No description
Uploaded on: February 22, 2023 -
June 2022 (v1)Journal article
No description
Uploaded on: February 22, 2023 -
August 2020 (v1)Journal article
We have previously identified male sex, younger age, and the presence of spinal cord lesions as independent factors that increase the 5-year risk for evolution from radiologically isolated syndrome (RIS) to multiple sclerosis. Here, we investigate risk factors for the development of a clinical event using a 10-year, multinational,...
Uploaded on: December 3, 2022 -
January 2022 (v1)Journal article
Background and objectives: Progressive multifocal leukoencephalopathy (PML) is a disabling neurologic disorder resulting from the infection of the CNS by JC polyomavirus in immunocompromised individuals. For the last 2 decades, increasing use of immunotherapies leads to iatrogenic PML. Iatrogenic PML is often associated with signs of...
Uploaded on: December 3, 2022 -
2022 (v1)Journal article
Background and objectives: To evaluate the predictive value of serum neurofilament light chain (sNfL) and CSF NfL (cNfL) in patients with radiologically isolated syndrome (RIS) for evidence of disease activity (EDA) and clinical conversion (CC).Methods: sNfL and cNfL were measured at RIS diagnosis by single-molecule array (Simoa). The risk of...
Uploaded on: October 13, 2023 -
July 2018 (v1)Journal article
BACKGROUND: Chronic visual loss is a disabling feature in patients with multiple sclerosis (MS). It was recently shown that MD1003 (high-dose pharmaceutical-grade biotin or hdPB) may improve disability in patients with progressive MS.OBJECTIVE: The aim of this study was to evaluate whether MD1003 improves vision compared with placebo in MS...
Uploaded on: December 4, 2022 -
July 2021 (v1)Journal articleSerum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
Objectives: The study aimed to assess the potential for serum neurofilament light chain (NFL) levels to predict the risk of progressive multifocal leukoencephalopathy (PML) in natalizumab (NTZ)-treated patients with multiple sclerosis (MS) and to discriminate PML from MS relapses.Methods: NFL levels were measured with single molecule array...
Uploaded on: December 3, 2022 -
April 2014 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
February 21, 2023 (v1)Journal article
Background and objectives: Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease activity at treatment start and under therapy, which may provide new clues on the mechanisms...
Uploaded on: October 9, 2024 -
October 26, 2022 (v1)Publication
Introduction: Nowadays, mandatory vaccination in patients with multiple sclerosis (MS) is widely recommended. Regarding COVID19, the absence of specific warnings led to the proposal of vaccination in patients with inflammatory diseases of the central nervous system. However global vaccination hesitancy remains and potential effect of COVID19...
Uploaded on: October 23, 2024 -
2020 (v1)Journal article
Background: Longitudinally extensive transverse myelitis (LETM) is classically related to aquaporin (AQP4)-antibodies (Ab) neuromyelitis optica spectrum disorders (NMOSD) or more recently to myelin oligodendrocyte glycoprotein (MOG)-Ab associated disease. However, some patients remain negative for any diagnosis, despite a large work-up...
Uploaded on: December 4, 2022 -
August 2021 (v1)Journal article
BACKGROUND: Sex steroids could explain the course of multiple sclerosis (MS) in pregnancy. OBJECTIVE: To compare the annualized relapse rate (ARR) 12 weeks post-partum in women treated with nomegestrol acetate (NOMAc) and 17-beta-estradiol (E2) versus placebo. METHODS: POPARTMUS is a randomized, proof-of-concept trial in women with MS,...
Uploaded on: December 4, 2022 -
February 2024 (v1)Journal article
Importance: Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack consensus.Objective: To assess the real-world association of HET as an index treatment compared with MET...
Uploaded on: February 16, 2024